Prelude Therapeutics Inc - 8-K Filing

Prelude Therapeutics reports Q3 2026 results with $142.7 million in cash runway extending into Q2 2028. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $PRLD

Read the full article at SEC EDGAR

More Regulatory news